A rationale for the use of anticoagulation in heart failure management

Journal of Thrombosis and Thrombolysis

Volumn 17, Issue 2, 2004, Pages 87-93

  Pulerwitz, Todd ^a   Rabbani, LeRoy E ^a   Pinney, Sean P ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Aspirin; Heart failure; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN SYNTHASE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOMYOPATHY; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SINUS RHYTHM; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; THROMBOGENESIS;

ANTICOAGULANTS; CLINICAL TRIALS; DISEASE MANAGEMENT; HEART FAILURE, CONGESTIVE; HUMANS; THROMBOEMBOLISM;

EID: 4444237010     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000037663.81512.71     Document Type: Review

References (38)

1. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-712.
2. Anonymous. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38A.
3. Loh E, Sutton MSJ, Wun CCC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
4. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080.
5. Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction - A population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208-216.
6. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994 343:687-691.
7. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in patients in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979.
8. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999;3:1424-1426.
9. Jafri SM, Ozawa T, Mammern E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and thrombolytic activation in patients with heart failure. Eur Heart J 1993;14:205-212.
10. Yamamoto K, Ikeda U, Furuhashi K, Irokowa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995;25:1634-1640.
11. Hoffmeister J, Hetzel S, Sander S, Kron M, Hombach V, Koenig W. Plasma viscosity and fibrinogen in relation to haemodynamic findings in chronic congestive heart failure. Eur J Heart Fail 1999;1:293-295.
12. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001;103:1746-1751.
13. Brown NJ, Vaughan DE. Role of angiotensin II in coagulation and fibrinolysis. Heart Fail Rev 1999;3:193-198.
14. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-447.
15. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987 ;2:3-9.
16. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985;66:835-839.
17. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982 306:1018-1022.
18. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly: The Framingham Study. Arch Intern Med 1987 147:1561-1564.
19. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
20. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
21. Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
22. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996 348:633-638.
23. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. J Am Coll Cardiol 2001;2101-2113.
24. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: Can clinical factors identify patients at increased risk? J Cardiovasc Risk 1995;2:97-102.
25. Fuster V, Gersh BJ, Giulliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-530.
26. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Eng J Med 1990;323:137-152.
27. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
28. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-753.
29. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(Suppl VI):VI-94-101.
30. Vaitkus P, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: A meta-analysis. J Am Coll Cardiol 1993;22:1004-1009.
31. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
32. Meune C, Mahe I, Mourad JJ, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: A review. Eur J Clin Pharmacol 2000;56:609-620.
33. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992 ;20:1549-1555.
34. Cleland JGF. Anticoagulant and anti-platelet therapy in heart failure. Curr Opinion Cardiol 1997;12:276-287.
35. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000 54:288-294.
36. Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5:357-382.
37. Konstam MA, Dracup K, Baker D, et al. Heart Failure: Evaluation and care of patients with left ventricular systolic dysfunction. Agency for Health Care Policy and Research, U.S. Dept. of Health and Human Services, Rockville, MD, 1994.
38. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. Circulation 1999;100:1016-1030.